Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

H. Kertland,M. Kays
DOI: https://doi.org/10.4212/CJHP.V66I5.1292
2013-10-22
The Canadian Journal of Hospital Pharmacy
Abstract:The current Canadian and US guidelines for communityacquired pneumonia (CAP) recommend azithromycin alone in mild cases and azithromycin in combination with a ß-lactam for patients admitted to hospital with moderate to severe CAP. To demonstrate that azithromycin should not be considered an alternative for the treatment of CAP, a medication assessment— based on indication, effectiveness, and safety—will be completed.
What problem does this paper attempt to address?